FOLD Stock Amicus Therapeutics Inc - Complete Overview

Nasdaq / Pharmaceutical Products / Healthcare / FOLD Stock

Amicus Therapeutics Inc (FOLD) price per share as of 16 Feb 2018
USD
Your sentiment
COLDTRENDOMETERHOT
Shares Outstanding 166.27M
Avg Daily Volume 2.63M
Market Cap 2.19B
Volatility 58.64% MEDIUM

AMICUS THERAPEUTICS INC (FOLD) OVERVIEW

FOLD stock is a pharmaceutical products company traded on Nasdaq. It is valued at 2.19B US dollars. There are 166.27M shares outstanding which Amicus Therapeutics Inc issued to investors. Volatility of the stock is MEDIUM, and the daily volume is 58.64% stock on average. It brought investors a total return of 141.95% over the last 12 months. Amicus Therapeutics Inc stock is relatively cheap. It's P/E ratio is below the market average.

Amicus Therapeutics Inc (FOLD) STOCK PRICE PERFORMANCE

FOLD SHAREHOLDER'S RETURN

Earnings Per Share 0.00
Dividends Per Share 0.00
12 Months Price Performance High
Total Return High

FOLD LATEST NEWS

3 Things In Biotech You Should Learn Today: February 14, 2018

Exelixis shows promise outside of liver and kidney cancer.Amicus Therapeutics gets priority review to put Fabry disease on FOLD.Audentes makes a BOLD move in Crigler-Najjar syndrome.

Amicus Therapeutics: Positive Data For Pompe Disease And Recent Regulatory Developments

The innovation of medicines to service the rare disease market can deliver hopes to countless patients worldwide.Amicus recently filed the NDA for migalastat with the U.S. FDA as a potential treatment

Amicus Gets Its NDA Through The Front Door... Can It Reach The Finish Line?

FDA accepts NDA review for migalastat for patients with Fabry disease. Migalastat also achieved priority review which cuts review time down to 6 months from 10 months. Fabry disease is a fatal disease

Amicus Therapeutics: Pompe Data Strengthens Bullish Thesis

The stock has been an admirable performer over multiple time frames.Pompe market opportunity appears attractive with 5,000 to 10,000 patients worldwide and 2016 global ERT sales reaching nearly $800 m

Amicus Therapeutics: What To Expect In 2018

Amicus enters 2018 with a strong commercial, financial and pipeline position. Galafold should continue to grow, expand to other territories and receive approvals in Japan and the U.S. Pompe program up

Amicus Therapeutics (FOLD) Surges: Stock Moves 9.2% Higher

Amicus Therapeutics (FOLD) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

Amicus Therapeutics Inc (FOLD) TECHNICAL INDICATORS

Name Value Action
RSI(14) 47.46 Neutral
CMO(14) -5.08 Sell
ADX(14) 26.50 N/A
Williams %R -52.93 Overbought

FOLD FORUM DISCUSSIONS

Keen to invest in cryptocurrencies? Read about these 20 most common mistakes to avoid them in your investments